ProfileGDS5678 / 1433983_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 83% 83% 82% 81% 81% 82% 83% 83% 82% 83% 86% 84% 86% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.0673983
GSM967853U87-EV human glioblastoma xenograft - Control 26.060183
GSM967854U87-EV human glioblastoma xenograft - Control 35.991982
GSM967855U87-EV human glioblastoma xenograft - Control 45.9908681
GSM967856U87-EV human glioblastoma xenograft - Control 55.8967281
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.7334682
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.875183
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.0418283
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.9183382
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.1468483
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.552686
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.2853184
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.5076786
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.2535584